Puma Biotechnology
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 185
- Market Cap
- $124.5M
- Introduction
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial ...
A Study of Alisertib in Combination with Endocrine Therapy in Patients with HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06369285
- Locations
- 🇺🇸
Alliance Cancer Specialists, Horsham, Pennsylvania, United States
🇪🇸Hospital ClÃnico Universitario de Valencia, València, Spain
🇺🇸Alabama Oncology, Birmingham, Alabama, United States
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06095505
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸The Oncology Institute of Hope and Innovation, Fort Lauderdale, Florida, United States
🇺🇸Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
- Conditions
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04366713
- Locations
- 🇵🇹
Hospital CUF Descobertas, Lisboa, Portugal
HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 1583
- Registration Number
- NCT03786107
- Locations
- 🇷🇸
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
🇺🇸Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇫🇷Institut Curie, Saint-Cloud, France
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 563
- Registration Number
- NCT02400476
- Locations
- 🇺🇸
Compassionate Care Research Group Inc., Riverside, California, United States
🇺🇸Emad Ibrahim, M.D., Inc., Redlands, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Santa Ana, California, United States
Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02334501
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
- Conditions
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 582
- Registration Number
- NCT01953926
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇮🇹Istituto Europeo di Oncologia (IEO) I.R.C.C.S., Milano, Italy
🇺🇸Gundersen Center for Cancer and Blood Disorders, La Crosse, Wisconsin, United States
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT01827267
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
- Conditions
- Interventions
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 621
- Registration Number
- NCT01808573
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of California San Diego Medical Center - Hillcrest, San Diego, California, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States
A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01142063
- Locations
- 🇺🇸
Investigational Site, New Haven, Connecticut, United States